Last reviewed · How we verify
Extubation U
Extubation U is a neuromuscular blocking agent that facilitates endotracheal tube removal.
Extubation U is a neuromuscular blocking agent that facilitates endotracheal tube removal. Used for Endotracheal tube removal.
At a glance
| Generic name | Extubation U |
|---|---|
| Also known as | Ultiva |
| Sponsor | Seganest |
| Drug class | Neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
It works by competitively inhibiting nicotinic acetylcholine receptors at the neuromuscular junction, leading to muscle relaxation and facilitating extubation. This effect is reversible, allowing for rapid recovery of neuromuscular function.
Approved indications
- Endotracheal tube removal
Common side effects
- Hypotension
- Respiratory depression
- Muscle weakness
Key clinical trials
- Ultrasound-Guided Versus Laparoscopy-Guided Transversus Abdominis Plane Block for Postoperative Analgesia (NA)
- The Clinical Value of Applying TOF and TcPO2 to Guide Elderly Patients Extubation (NA)
- Concentrations of Remifentanil for Extubation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extubation U CI brief — competitive landscape report
- Extubation U updates RSS · CI watch RSS
- Seganest portfolio CI